Shire Hall International has beaten off competition from two rivals to
win a global brief from pharmaceuticals giant Schering-Plough.
The agency, an arm of the WPP-owned Shire Hall Group, is tasked with
providing medical education and PR support for a pair of prescription
drugs made by Schering-Plough's cardiology division.
One is Integrilin, used by patients suffering from conditions such as
unstable angina. The other is Ezetimibe, claimed by the agency to be the
'first in a new class of cholesterol absorption inhibitors' and
currently in clinical development.
The account was won jointly with Shire Hall's US division, which will
work alongside International on the client. The business is led by Lois
Hall, the international unit's MD.